We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative Disorders

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00186576
First Posted: September 16, 2005
Last Update Posted: October 14, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
National Institutes of Health (NIH)
Information provided by:
Stanford University
  Purpose
To improve survival outcomes for patients with MDS and MPD with a nonmyeloablative allogeneic hematopoietic cell transplant.

Condition Intervention
Myelodysplastic Syndromes Myeloproliferative Disorders Blood and Marrow Transplant (BMT) Myelodysplastic Syndromes (MDS) Myeloproliferative Disorders (MPD) Procedure: nonmyeloablative allogeneic hematopoietic cell transplant

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)

Resource links provided by NLM:


Further study details as provided by Stanford University:

Primary Outcome Measures:
  • Efficacy of transplant [ Time Frame: 1 year ]

Secondary Outcome Measures:
  • safety profile of nonmyeloablative transplant, graft versus host disease, graft rejection, non-relapse mortality, use of donor lymphocyte infusion [ Time Frame: 1 year ]

Estimated Enrollment: 40
Study Start Date: December 2001
Study Completion Date: July 2010
Primary Completion Date: March 2004 (Final data collection date for primary outcome measure)
Detailed Description:
Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Treatment of Myelodysplastic Syndromes and Myeloproliferative Disorders (Except CML)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:- Myelodysplastic Syndromes

  • Myeloproliferative Disorders
  • HLA matched donor available

Exclusion Criteria:- organ dysfunction

  • HIV positive
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00186576


Locations
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
National Institutes of Health (NIH)
Investigators
Principal Investigator: Ginna Laport Stanford University
  More Information

Publications:
Responsible Party: Ginna Laport, Stanford University School of Medicine
ClinicalTrials.gov Identifier: NCT00186576     History of Changes
Obsolete Identifiers: NCT00052546
Other Study ID Numbers: BMT128
75826
First Submitted: September 14, 2005
First Posted: September 16, 2005
Last Update Posted: October 14, 2010
Last Verified: October 2010

Additional relevant MeSH terms:
Disease
Syndrome
Myelodysplastic Syndromes
Preleukemia
Myeloproliferative Disorders
Pathologic Processes
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Neoplasms